

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		
Is the requested medication: <input type="checkbox"/> New or <input type="checkbox"/> Continuation of Therapy? If continuation, list start date: _____		
Is this patient currently hospitalized? <input type="checkbox"/> Yes <input type="checkbox"/> No If recently discharged, list discharge date: _____		

Section B - Provider Information

First Name:	Last Name:	M.D./D.O.
Address:	City:	State: ZIP code:
Phone:	Fax:	NPI #: Specialty:
Office Contact Name / Fax attention to:		

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

**Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL for a list of preferred alternatives**

Member First name:	Member Last name:	Member DOB:
--------------------	-------------------	-------------

Clinical and Drug Specific Information

ALL REQUESTS

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a diagnosis of migraine headaches with or without aura?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a history of failure, contraindication, or intolerance any of the preferred products? <i>(If yes, complete Section D above)</i>

NARATRIPTAN

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a history of failure, contraindication, or intolerance to Imitrex (sumatriptan)? <i>(If yes, complete Section D above)</i>
--	--

QUANTITY LIMIT REQUESTS

DRUG NAME	STRENGTH	QUANTITY LIMIT
Amerge (naratriptan)	1mg, 2.5mg	9 tabs/month
Frova	2.5mg	9 tabs/month
Imitrex (sumatriptan)	25mg, 50mg, 100mg	9 tabs/month
Maxalt (rizatriptan)	5mg, 10mg	9 tabs/month
Maxalt MLT (rizatriptan)	5mg, 10mg	9 tabs/month
Axert	6.25mg, 12.5mg	6 tabs/month
Relpax	20mg, 40mg	6 tabs/month
Zomig (zolmitriptan)	2.5mg	6 tabs/month
Zomig ZMT (zolmitriptan)	2.5mg	6 tabs/month
Imitrex (sumatriptan) nasal spray	5mg, 20mg	6 spray devices/month
Zomig Nasal Spray	5mg	2 sprays/day
Treximet	85mg/500mg, 10mg/60mg	9 tabs/month
Zomig (zolmitriptan)	5mg	6 tabs/month
Zomig ZMT (zolmitriptan ODT)	5mg	6 tabs/month
SumaChip (sumatriptan & capsaicin-menthol)	100mg tab & capsaicin menthol 0.0375%	1 box (39 units)/month
Onzetra Xsail	11 mg	1 box (8 units)/month
Zembrace SymTouch	3 mg	1 box (4 units)/month
Sumavel DosePro	6 mg	1 box (6 units)/month
Imitrex (sumatriptan) injection	4mg, 6mg	2 devices/month

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the requested dosage meet the plan's quantity limit? <i>(See Table above)</i>
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the requested medication prescribed by, or in consultation, with a neurologist or pain management specialist?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the patient experiencing <u>two or more</u> headaches monthly?
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the patient currently receiving prophylactic therapy with at least <u>ONE</u> of the following? <i>(If yes, check which applies)</i> <ul style="list-style-type: none"> <input type="checkbox"/> Antidepressants [e.g., Elavil (amitriptyline), Effexor (venlafaxine)] <input type="checkbox"/> Antihistamines (e.g., cyproheptadine) <input type="checkbox"/> Antiepileptics [e.g., Depakote/Depakote ER (divalproex sodium), Topamax (topiramate)] <input type="checkbox"/> ACE Inhibitors [e.g., Zestril (lisinopril)] <input type="checkbox"/> Angiotensin receptor blockers [e.g., Atacand (candesartan)] <input type="checkbox"/> Alpha-agonists (e.g., clonidine, guanfacine) <input type="checkbox"/> Beta-blockers [e.g., Inderal (propranolol), Timolol, Toprol XL (metoprolol)]
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the provider acknowledge that the potential benefit outweighs the risk associated with the higher dose or quantity?

Provider Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.